ME (23andMe Holding Co) Cash-to-Debt : 1.77 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 23andMe Holding Co's cash to debt ratio for the quarter that ended in Sep. 2024 was 1.77.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 23andMe Holding Co could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for 23andMe Holding Co's Cash-to-Debt or its related term are showing as below:

ME' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.77 Med: 4.54 Max: 8.51
Current: 1.77

During the past 5 years, 23andMe Holding Co's highest Cash to Debt Ratio was 8.51. The lowest was 1.77. And the median was 4.54.

ME's Cash-to-Debt is ranked better than
59.56% of 225 companies
in the Medical Diagnostics & Research industry
Industry Median: 1 vs ME: 1.77

23andMe Holding Co Cash-to-Debt Historical Data

The historical data trend for 23andMe Holding Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

23andMe Holding Co Cash-to-Debt Chart

23andMe Holding Co Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

N/A

3.01

6.41

4.54

2.83

23andMe Holding Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial														3.16	3.08	2.83	2.29	1.77

Competitive Comparison of 23andMe Holding Co's Cash-to-Debt

For the Diagnostics & Research subindustry, 23andMe Holding Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

23andMe Holding Co's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's Cash-to-Debt falls into.

23andMe Holding Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

23andMe Holding Co's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	216.488	/	(8.67	+	67.845)
	=	2.83

23andMe Holding Co's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	126.601	/	(9.266	+	62.422)
	=	1.77

23andMe Holding Co (NAS:ME) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

23andMe Holding Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

23andMe Holding Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.23andme.com

23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Executives

Kathy L Hibbs	officer: See Remarks	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards	officer: Head of Therapeutics Discovery	160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage	officer: Interim CFO	490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan	officer: Head of Therapeutics	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell	director, officer: Chief Financial Officer	27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md	director	BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson	officer: VP, General Manager-Consumer	440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim	officer: See Remarks	6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon	officer: Vice President, Engineering	1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch	officer: See Remarks	2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler	officer: Vice President, People	1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p.	10 percent owner	2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc	10 percent owner	171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki	director, 10 percent owner, officer: Chief Executive Officer	C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606